Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. While the trophon device patent only extends to 2025, Quinn says the revenue stream generated by consumables will last beyond a decade.Quinn has excluded an expansion of the product into China, citing a lack of clinical support, but she expects it to be successful in Japan. Intraday 1w 1m 3M 1y 3y 5y Max Price. We look forward to helping you on your financial journey.You now have access to Intelligent Investor Free Insights. Last name is required. any of each other's Investing.com's posts.Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.Sign up to create alerts for Instruments, However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.By doing so, you and %USER_NAME% will not be able to see Your status will be reviewed by our moderators.Please wait a minute before you try to comment again.Thanks for your comment. Dividend.
You can find more details by going to one of the sections under this page such as ex-date, dividend and payment date. Please refer to our Financial Services Guide (FSG) for more information at Notable Dividend: Unable to evaluate NAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts. If you ask me if the NAN share price keeps falling this could be a great opportunity for savvy long-term investors. International Sites: Nanosonics does not currently pay a dividend. First name is required. Brokerage costs are not included in this calculation. All Rights Reserved Get information about Nanosonics dividends and ex-dividend dates. Copyright © 1999-2020 InvestSMART Financial Services Pty Ltd. All rights reserved | Australian Financial Services Licensee: AFSL # 226435 | ABN 70 089 038 531 | Network Nanosonics Podcasts; News & Events. You now have access to Free InvestSMART Insights, we look forward to helping you on your financial journey.You now have access to Free Eureka Report Insights. Economic Events and content by followed authors At midday on Friday, it was down about 6.5 per cent at $6.58, amid a broader sell-off.The company is led by Michael Kavanagh, who joined in 2013, having previously spent a decade at hearing implant maker and Morningstar wide-moat stock The trophon was launched in 2009 and is a pioneer product in preventing infection in healthcare settings. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You can find more details by going to one of the sections under this page such as ex-date, dividend and payment date.
NAN Dividends Get information about Nanosonics dividends and ex-dividend dates. It is also involved in research, development and commercialization of infection control and decontamination products and related technologies. For more information about fees and costs, please see the Here you will find our ASX announcements, annual reports, presentations and important information to help you manage your shareholding.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.Registration for this event is available only to Eureka Report members. InvestSMART cannot determine whether or not franking has been included, nor if dividends have been reinvested. It has installed about 20,000 trophon units in an addressable market of about 120,000.Quinn expects the company to expand its market share in North America and Europe over the coming decade and generate steady revenue from trophon accessories or “consumables”.However, she has set a high uncertainty rating on the company for two reasons: its patents expire in 2025 and the company is yet to reveal the extent of its product pipeline.Quinn will review her rating when more detail emerges.“Our different view to the market likely stems from lower ultimate penetration rates for trophon and the inclusion of only the single potential product that is in the clinical trial phase in our valuation,” Quinn says.“On the existing trophon product, the most significant risk relates to the expiry of the key patents for the device in 2025 and the possibility of a copycat product coming to market thereafter. 'Eureka Report' : 'Intelligent Investor' }} 15-day trial.The email address you entered is registered with InvestSMARTWe have sent you an email with the details of your registration. Ultrasound probe reprocessing training with trophon2. News; Clinical e-Alerts; Events; Contact. Your status will be reviewed by our moderators.Please wait a minute before you try to comment again.Thanks for your comment. The Nanosonics share price reached a low of $4.01 in March, a discount of 36% on today’s price.
Our team of analysts provide weekly insights & analysis into undervalued ASX shares to help you build a market beating portfolio.Our research tools allow you to search, filter and compare thousands of securities listed on the ASX.A simple way to monitor all your investments in one easy place such as ASX shares, dividends, funds & more.Our team of analysts provide weekly insights & analysis into undervalued ASX shares to help you build a market beating portfolio.Our research tools allow you to search, filter and compare thousands of securities listed on the ASX.A simple way to monitor all your investments in one easy place such as ASX shares, dividends, funds & more.